I've always loved the life sciences, and have been fortunate to have my career take place during a time of profound advances in biology.
Jason Rhodes
Vice President, Business Development, Alnylam
(JOHN HALPERN)
I've always loved the life sciences, and have been fortunate to have my career take place during a time of profound advances in biology. My first project was a Phase III trial acceleration strategy for what was then Sandoz, now Novartis. That experience provided me with invaluable exposure to many of the central elements of the pharma industry, and gave me a keen appreciation of the challenge of meeting patients' needs in a demanding regulatory environment. The common thread throughout my career has been identifying and realizing new business opportunities based on novel science and technology, and translating new science into successful business opportunities for the benefit of patients and shareholders.
When I joined Alnylam, my daily activities actually became relatively more hands-on compared to my venture capital role. Alnylam's business strategy is to enable the industry to practice RNAi through creative partnerships with a long-term orientation. These partnerships are highly symbiotic with our own product pipeline and business. We use the Greek word for innovation, "kainotomia," to describe our culture and approach, and we are innovative in every aspect of what we do, from science through business. I'm looking forward to continuing to play a role as a leader at Alnylam as we realize the tremendous potential of RNAi in areas such as stem cells, vaccines, bioprocessing, and other applications. It's tremendously gratifying—and a lot of fun—to be part of it.
The Weight-Loss Gold Rush: Legal and Regulatory Implications
July 11th 2024Jim Shehan, chair of the FDA Regulatory practice, Lowenstein Sandler, discusses how the FDA and other regulators likely to respond to the increased public interest and potential off-label use of GLP-1 drugs, what needs to be done for GLP-1s to be covered, advice for investors and financiers considering entering the weight-loss medication market and more.
Healthcare Marketing Strategies for Reaching Diverse Audiences
May 14th 2024Amanda Powers-Han, Chief Marketing Officer, Greater Than One, and Pharmaceutical Executive Editorial Advisory Board member, discusses how improved DE&I in healthcare marketing strategies can not only reach diverse audiences more effectively but also contribute to improved patient care outcomes, challenges faced in crafting culturally sensitive messages, and much more.